Dr. Saba Discusses Ongoing Research in Head and Neck Cancer
October 11th 2019Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.
Dr. Ramalingam on the Activity of Osimertinib Combinations in NSCLC
September 6th 2019Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).
Dr. Saba on Investigational Deintensification Approaches in HPV-Related HNSCC
August 15th 2019Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses investigational deintensification approaches in HPV-related oropharyngeal squamous cell carcinoma.
Dr. Gogineni on De-Escalation Strategies in HER2+ Breast Cancer
August 14th 2019Keerthi Gogineni, MD, MSHP, an assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses de-escalation strategies in HER2-positive breast cancer.
Dr. Bhave Discusses [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer
August 12th 2019Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.
Dr. Saba on Treatment Deintensification in HPV-Related Oropharyngeal Squamous Cell Carcinoma
August 1st 2019Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses treatment deintensification for patients with HPV-related oropharyngeal squamous cell carcinoma.
Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer
August 1st 2019Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.
Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLC
July 19th 2019Jennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.
Dr. Lonial on Encouraging Data With Emerging Agents in Myeloma
April 5th 2019Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.
Dr. Lonial on Treatment of Patients With Late Relapse Myeloma
March 7th 2019Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the treatment of patients with late relapse myeloma.
Findings for Pembrolizumab Plus mFOLFOX6 in Advanced CRC
January 9th 2019Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).
Dr. Cohen Discusses CAR T-Cell Therapy in MCL
November 20th 2018Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.
Rationale for Pembrolizumab Plus mFOLFOX6 in Advanced CRC
November 15th 2018Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.